Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AssigneeAllergan, Inc.
InventorsYariv Donde, Robert M. Burk, Michael Garst
Life of this patent
Estimating the term…
Abstract
A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.
Claims20
A method for treating glaucoma or elevated intraocular pressure comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising one or more excipients and a compound, wherein the composition is an ophthalmically acceptable liquid, and wherein said compound has an α and an ω chain, and is represented by a formula:
- or a derivative thereof, wherein said derivative has a structure as shown above except that 1 or 2 alterations are made to the α chain and/or the ω chain, and wherein an alteration consists of:
- a. adding or removing 1 non-hydrogen atom selected from S, O, C or a halogen, or substituting 1 non-hydrogen atom selected from S, O, C or a halogen for 1 different non-hydrogen atom selected from S, O, C or a halogen, or
- b. changing the bond order of 1 existing covalent bond without adding or deleting said bond;
- wherein hydrogen atoms are added as removed as appropriate for the type of alteration;
- or a pharmaceutically acceptable salt, or tetrazole thereof.
A compound having an α chain and an ω chain that is represented by a formula:
- or a derivative thereof having a structure as shown above except that 1 or 2 alterations are made to at least one of the α chain and the ω chain, and wherein an alteration consists of:
- a. adding or removing 1 non-hydrogen atom selected from S, O, C or a halogen, or substituting 1 non-hydrogen atom selected from S, O, C or a halogen for 1 different non-hydrogen atom selected from S, O, C or a halogen, or
- b. changing the bond order of 1 existing covalent bond without adding or deleting said bond;
- wherein hydrogen atoms are added as removed as appropriate for the type of alteration;
- or a pharmaceutically acceptable salt, or tetrazole thereof.
Dependencies are inferred from the claim text.